Literature DB >> 10861310

Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells.

M S Orr1, P M O'Connor, K W Kohn.   

Abstract

BACKGROUND: Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, in breast tumors has been linked with either increased or decreased response of breast cancer patients to various therapies. In breast cancer cell lines, overexpression of exogenous c-erbB2 sometimes alters drug sensitivities but sometimes has no effect. To avoid the genetic complexities associated with established cancer cell lines, normal human mammary epithelial cells (HMECs) were studied to determine whether c-erbB2 overexpression by itself would alter chemosensitivity.
METHODS: HMECs were designed to overexpress c-erbB2, and these cells were then evaluated for alterations in chemosensitivity.
RESULTS: HMECs overexpressing c-erbB2 failed to show any alterations in chemosensitivity to a panel of chemotherapeutic agents, as indicated by 95% confidence intervals on growth curves of cells treated with or without the agent of interest. With the use of fluorescence-activated cell sorting to enrich for HMECs overexpressing c-erbB2 on their surface, an 85% pure population of cells was isolated and their chemosensitivity was evaluated. Again, the cells failed to display any alterations in chemosensitivity.
CONCLUSIONS: These results suggest that overexpression of c-erbB2 is not sufficient by itself to induce changes in chemosensitivity. Cellular studies using normal human cells in which the complexity of the system can be carefully controlled by the addition of one, two, or even more genes associated with cancer development may provide valuable information about how the products of the genes interact with each other and which combinations are critical in regulating chemosensitivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861310     DOI: 10.1093/jnci/92.12.987

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.

Authors:  M Schmidt; A Bachhuber; A Victor; E Steiner; M Mahlke; H A Lehr; H Pilch; W Weikel; P G Knapstein
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-25       Impact factor: 4.553

3.  Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro.

Authors:  Sarah N Cross; Emiliano Cocco; Stefania Bellone; Valsamo K Anagnostou; Stacey L Brower; Christine E Richter; Eric R Siegel; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Am J Obstet Gynecol       Date:  2010-04-24       Impact factor: 8.661

4.  Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer.

Authors:  Päivikki Kauraniemi; Tuula Kuukasjärvi; Guido Sauter; Anne Kallioniemi
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

5.  Expression of circadian clock gene human Period2 (hPer2) in human colorectal carcinoma.

Authors:  Yaping Wang; Luchun Hua; Chao Lu; Zongyou Chen
Journal:  World J Surg Oncol       Date:  2011-12-13       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.